Primary Objective: To evaluate the effect of one-year Alglucosidase alfa treatment on motor function \[Six-minute walk test (6MWT) and lung function predicted Forced vital capacity (FVC)\] among Chinese Late Onset Pompe Disease patients above 5 years old. To evaluate the safety of Myozyme 20mg/kg, IV biweekly in Chinese LOPD patients above 3 years old. Secondary Objective: To evaluate the effect of one-year treatment with Alglucosidase alfa on improvement of manual muscle test (MMT), Maximal inspiratory and expiratory pressure (MIP and MEP)\], Quick Motor Function Test scores, and health-related quality of life (SF-12) among LOPD patients over 5 years old.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change from baseline in Six-minute walk test (6MWT) for the patients ≥5-year old
Timeframe: Baseline to 12 months
Change from baseline in percent predicted forced vital capacity (%FVC) in upright position for the patients ≥5-year old
Timeframe: Baseline to 12 months
Number of participants with adverse events Number of AEs
Timeframe: From signing the ICF to the 30th day after the last dosage of the study medications